2-甲硫基-4,5-嘧啶二甲酸二乙酯 | 149771-08-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-甲硫基-4,5-嘧啶二甲酸二乙酯
• 中文别名: 2-(甲基硫代)-4,5-嘧啶二羧酸二乙酯
• 英文名称: ethyl 4-(ethoxycarbonyl)-2-methylthiopyrimidine-5-caboxylate
• 英文别名: 2-methylsulfanyl-pyrimidine-4,5-dicarboxylic acid diethyl ester；Diethyl 2-(methylthio)-4,5-pyrimidinedicarboxylate；diethyl 2-methylsulfanylpyrimidine-4,5-dicarboxylate
• CAS: 149771-08-4
• 化学式: C₁₁H₁₄N₂O₄S
• 分子量: 270.309
• InChiKey: RVHLRUKDQWAVPR-UHFFFAOYSA-N

物化性质

• 熔点：
  53 - 54°C
• 沸点：
  367.7±22.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  104
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• 海关编码：
  2933599090
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Diethyl 2-(methylthio)-4,5-pyrimidinedicarboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Diethyl 2-(methylthio)-4,5-pyrimidinedicarboxylate
CAS number: 149771-08-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H14N2O4S
Molecular weight: 270.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲硫基-4,5-嘧啶二甲酸二乙酯 在 sodium hydroxide 、 草酰氯 作用下， 以 乙醇 、 二氯甲烷 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.5h， 生成 6-{[3,5-bis(trifluoromethyl)phenyl]methyl}-2-methylthio-3-pyrrolino[3,4-d]pyrimidine-5,7-dione
  参考文献：
  名称：

  Palanki, Moorthy S.S.; Erdman, Paul E.; Goldman, Mark E., Medicinal Chemistry Research, 2000, vol. 10, # 1, p. 19 - 29

  摘要：

  DOI：
• 作为产物：
  描述：

  草酰乙酸二乙酯 在 sodium 作用下， 以 乙醇 为溶剂， 反应 1.5h， 生成 2-甲硫基-4,5-嘧啶二甲酸二乙酯
  参考文献：
  名称：

  Palanki, Moorthy S.S.; Erdman, Paul E.; Goldman, Mark E., Medicinal Chemistry Research, 2000, vol. 10, # 1, p. 19 - 29

  摘要：

  DOI：

文献信息

• Hiv integrase inhibitors
  申请人：Verschueren Wim Gaston

  公开号：US20060211724A1

  公开（公告）日：2006-09-21

  The present invention concerns the compounds having the formula (1), N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof wherein (a) or (b); A, together with the two carbons of the phenyl ring to which it is attached forms a monocyclic aryl or a monocyclic Het 2 ; R 1 is hydrogen, halo, nitro, cyano, sultam, sultim, C 3-7 cycloalkyl, C(═O)—R 5 , S(═O) y —R 6 , OR 7 , NR 8 R 9 , C(═NR 8 )—R 5 , optionally polysubstituted C 1-6 alkyl, optionally polysubstituted C 2-6 alkenyl or optionally polysubstituted C 2-6 alkynyl; R 2 is hydrogen, C 3-7 cycloalkyl, aryl, Het 1 , Het 2 , C(═O)—R 5 , S(═) y —R 6 OR 7 , NR 8 R 9 , C═NR 8 )—R 5 , or optionally polysubstituted C 1-6 alkyl, optionally polysubstituted C 2-6 alkenyl or optionally polysubstituted C 2-6 alkynyl. It further relates to their use as HIV integrase inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. It also concerns combinations thereof with other anti-retroviral agents, and to their use in assays as reference compounds or as reagents.

  本发明涉及具有式（1）的化合物，N-氧化物，盐，立体异构体，外消旋混合物，前药，酯和其代谢物，其中（a）或（b）; A与其附着的苯环的两个碳形成单环芳基或单环Het2; R1是氢，卤素，硝基，氰基，磺酰胺，磺酰亚胺，C3-7环烷基，C（═O）-R5，S（═O）y-R6，OR7，NR8R9，C（═NR8）-R5，可选地多取代的C1-6烷基，可选地多取代的C2-6烯基或可选地多取代的C2-6炔基; R2是氢，C3-7环烷基，芳基，Het1，Het2，C（═O）-R5，S（═）y-R6OR7，NR8R9，C═NR8）-R5，或可选地多取代的C1-6烷基，可选地多取代的C2-6烯基或可选地多取代的C2-6炔基。它进一步涉及它们作为HIV整合酶抑制剂的用途，它们的制备过程以及包含它们的制药组合物和诊断试剂盒。它还涉及它们与其他抗逆转录病毒药物的组合，以及它们作为参考化合物或试剂在测定中的使用。
• [EN] HIV INTEGRASE INHIBITORS<br/>[FR] INHIBITEURS D'INTEGRASE VIH
  申请人：TIBOTEC PHARM LTD

  公开号：WO2004096807A3

  公开（公告）日：2005-01-06
• Sansebastiano; Mosti; Menozzi, Il Farmaco, 1993, vol. 48, # 3, p. 335 - 355
  作者：Sansebastiano、Mosti、Menozzi、Schenone、Muratore、Petta、Debbia、Pesce Schito、Schito

  DOI：——

  日期：——
• HIV INTEGRASE INHIBITORS
  申请人：Tibotec Pharmaceuticals Ltd.

  公开号：EP1625130A2

  公开（公告）日：2006-02-15
• Palanki, Moorthy S.S.; Erdman, Paul E.; Goldman, Mark E., Medicinal Chemistry Research, 2000, vol. 10, # 1, p. 19 - 29
  作者：Palanki, Moorthy S.S.、Erdman, Paul E.、Goldman, Mark E.、Suto, Carla、Suto, Mark J.

  DOI：——

  日期：——